» Articles » PMID: 19118054

Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses

Abstract

Purpose: Antigenic overlap among circulating endothelial cells (CEC) and progenitors (CEP), platelets, and other blood cells led to the need to develop a reliable standardized method for CEC and CEP quantification. These cells are emerging as promising preclinical/clinical tools to define optimal biological doses of antiangiogenic therapies and to help stratify patients in clinical trials.

Experimental Design: We report the experimental validation of a novel flow cytometry method that precisely dissects CEC/CEP from platelets and other cell populations and provides information about CEC/CEP viability.

Results: Sorted DNA/Syto16(+)CD45(-)CD31(+)CD146(+) CECs, investigated by electron microscopy, were found to be bona fide endothelial cells by the presence of Weibel-Palade bodies. More than 75% of the circulating mRNAs of the endothelial-specific gene, VE-cadherin, found in the blood were present in the sorted population. CECs were 140 +/- 171/mL in healthy subjects (n = 37) and 951 +/- 1,876/mL in cancer patients (n = 78; P < 0.0001). The fraction of apoptotic/necrotic CECs was 77 +/- 14% in healthy subjects and 43 +/- 23% in cancer patients (P < 0.0001). CEPs were 181 +/- 167/mL in healthy donors and 429 +/- 507/mL in patients (P = 0.00019). Coefficients of variation were 4 +/- 4% (intrareader), 17 +/- 4% (interreader), and 17 +/- 7% (variability over 0-72 h), respectively. Parallel samples were frozen by a standardized protocol. After thawing, coefficients of variation were 12 +/- 8% (intrareader), 16 +/- 10% (interreader), and 26 +/- 16% (variability over 0-14 days of frozen storage), respectively.

Conclusions: This procedure enumerates a truly endothelial cell population with limited intrareader and interreader variability. It appears possible to freeze samples for large-scale CEC enumeration during clinical trials. This approach could be enlarged to investigate other angiogenic cell populations as well.

Citing Articles

Endothelial progenitor cells as an angiogenic biomarker for the diagnosis and prognosis of lung cancer.

Najjar F, Alsabe H, Sabbagh H, Al-Massarani G, Aljapawe A, Alamalla N Rep Pract Oncol Radiother. 2025; 29(5):544-557.

PMID: 39759554 PMC: 11698562. DOI: 10.5603/rpor.102618.


Novel Biomarkers and the Multiple-Marker Approach in Early Detection, Prognosis, and Risk Stratification of Cardiac Diseases: A Narrative Review.

Ullah A, Sajid S, Qureshi M, Kamran M, Anwaar M, Naseem M Cureus. 2023; 15(7):e42081.

PMID: 37602073 PMC: 10434821. DOI: 10.7759/cureus.42081.


Increased number of endothelial progenitor cells in the blood of patients with psoriasis vulgaris.

Malkowska J, Sliwinska J, Dziembowska I, Ziolkowska K, Boinska J, Goralczyk B Postepy Dermatol Alergol. 2023; 38(2):214-221.

PMID: 36751552 PMC: 9880778. DOI: 10.5114/ada.2021.106199.


Are circulating endothelial cells the next target for transcriptome-level pathway analysis in ARDS?.

Costa Monteiro A, Matthay M Am J Physiol Lung Cell Mol Physiol. 2023; 324(4):L393-L399.

PMID: 36749906 PMC: 10110698. DOI: 10.1152/ajplung.00353.2022.


Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes.

Cella C, Spada F, Berruti A, Bertolini F, Mancuso P, Barberis M Cancers (Basel). 2022; 14(18).

PMID: 36139632 PMC: 9497075. DOI: 10.3390/cancers14184471.